[144] Olema Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Olema Pharmaceuticals, Inc. filed a Form 144 reporting a proposed sale of 11,914 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $95,826.88. The filing lists approximately 68,634,329 shares outstanding and an approximate sale date of 09/16/2025 on the NASDAQ. The shares being offered consist of 10,000 founder shares acquired on 03/20/2007 (recorded as compensation) and 1,914 shares purchased in the open market on 06/30/2014 for cash. The filer certifies no undisclosed material adverse information about the issuer and references Rule 10b5-1 plan language if applicable.

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 disclosure of a small insider sale; compliance and timing are the primary considerations.

The Form 144 reports a proposed sale under Rule 144 of 11,914 common shares with a stated aggregate value of $95,826.88, to be executed via Fidelity on NASDAQ around 09/16/2025. The filing details acquisition dates and nature: 10,000 founder shares from 03/20/2007 recorded as compensation and 1,914 acquired on 06/30/2014 in open market transactions for cash. There are no reported sales in the prior three months. The document includes the standard attestation that no material nonpublic information is known and references Rule 10b5-1 plan adoption language. From a compliance standpoint, the filing appears to include the required elements for a Form 144.

Corporate Governance Specialist

TL;DR: Disclosed sale is modest relative to outstanding shares; governance impact is likely minimal.

The proposed disposition equals roughly 0.017% of the reported outstanding share count (11,914 of 68,634,329). The breakdown between long-held founder shares and later open-market purchases is provided, and no recent sales in the last three months are reported. The attestation language about lack of material nonpublic information and possible 10b5-1 plan adoption is included, which aligns with good governance practice for insider liquidity events. The filing is concise and contains the standard confirmations required for insider sales under Rule 144.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	11914	95826.88	68634329	09/16/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/20/2007	Founder Shares	Issuers			10000	03/20/2007	Compensation
Common	06/30/2014	Open Market Purchase	Issuers			1914	06/30/2014	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Olema Pharmaceuticals' (OLMA) Form 144 report?

The filing reports a proposed sale of 11,914 common shares via Fidelity with an aggregate market value of $95,826.88, approximate sale date 09/16/2025 on NASDAQ.

How many shares outstanding does Olema report in the Form 144?

The filing lists 68,634,329 shares outstanding.

What is the acquisition history of the shares being sold for OLMA?

The seller acquired 10,000 founder shares on 03/20/2007 (compensation) and 1,914 shares on 06/30/2014 via open-market purchase paid in cash.

Has the filer sold OLMA securities in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.

Does the Form 144 indicate the filer knows any undisclosed material information?

By signing the notice the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.